Building a system to ensure awareness of nirogacestat, a treatment for desmoid tumors

Summary

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that arise in connective tissues such as fascia, ligaments, and tendons.The FDA first approved nirogacestat for use in adult patients in 2023.1 The product has a broad indication and can be used in adult patients with progressing desmoid tumors that require systemic treatment.Although nirogacestat is used in a rare disease, it is widely available in oncology practices that dispense oral therapies as well as through specialty pharmacies for practices that do not have access to oral therapies.